We are ONE team,
working towards ONE goal to
ONE molecule at a time.
One in a Few Billion
There are three billion letters, three billion nucleotides that make up our genome. Our proprietary technology has the ability to detect and quantify disease at single base-pair resolution. Our name speaks to this unique technology, and we are focused on applying it to various disease states to help
At the Forefront of Disease Detection
Our proprietary Quantitative Counting Templates, or QCTs™, power our ability to detect and measure tiny and sparse disease-related DNA fragments, or molecules, at the single base-pair level. Several common and severe recessive conditions screened for prenatally can be caused by single-base pair alterations.
Our QCT technology enables quantifying these tiny variations using cell-free DNA. We believe this quantification will open the door to exponential improvements in prenatal screening, liquid biopsy, and beyond.
Moving Prenatal Screening and Oncology Testing Forward
We assess fetal risk for recessive conditions and aneuploidies from maternal blood.
UNITY Screen™ includes a carrier screen as well as a single-gene (for recessive conditions) and aneuploidy NIPT and only requires a maternal blood draw at 10+ weeks to assess fetal risk. No paternal sample needed.
Northstar Select™ and Northstar Response™ are now available for commercial use.
Northstar Select™ helps determine the most appropriate first line therapy, and Northstar Response™ helps monitor if the therapy is working.
“I love being able to introduce the latest and greatest technology to Women’s Health providers that will improve their knowledge on each pregnancy and give babies the best shot at healthy beginnings!”
Christy Brit |
Sr. Account Executive
“BillionToOne’s leadership values growth of the company’s employees and equality among peers.”
Aaron Aquino | Office Manager
“I love BillionToOne’s culture, everyone is so welcoming and always open to lend a helping hand.”
LaJhane Lyons |
Sr. Client Service Representative
“We have a very strong culture of cross-departmental teamwork. Everyone here cares about making an impact!”
John Fang |
Manager of Bioinformatics
Coupling Careers with Great Culture
What unites our team and drives us forward is one goal of making molecular testing more accurate, efficient, and accessible to all. This special group of bright and talented people is improving healthcare. If this appeals to you, consider joining us.
Leading with Passion and Purpose
Co-founders Oguzhan Atay, Ph.D., and David Tsao, Ph.D., and our team of engineers, scientists, and industry experts care deeply about every sample that comes into our lab.
News & Media
What we offer
- Our Technology
- Publication
- Products
Explore
- News & Media
- Press Releases
- Media Coverage
- Events
- Social Media
About us
- Contact Information
- Careers
- Provider Portal
- Patient Portal
contact
- Contact Information
- Careers
- Provider Portal
- Patient Portal
© 2024 BillionToOne Inc.
All rights reserved.